I'm sure your doctor knows all about this.
Trials 2014, 15:316
doi:10.1186/1745-6215-15-316
Published: 8 August 2014
Published: 8 August 2014
Abstract (provisional)
Background
Stroke has a huge impact, leaving more than a third of affected people with lasting
disability and rehabilitation remains a cornerstone treatment in the National Health
Service (NHS). Recovery of mobility and arm function post-stroke occurs through re-learning
to use the affected body parts and/or learning to compensate with the lesser affected
side. Promising evidence suggests that the addition of Co-careldopa to physical therapy
and occupational therapy may improve the recovery of arm and leg movement and lead
to improved function.
Methods
Dopamine Augmented Rehabilitation in Stroke (DARS) is a multi-centre double-blind,
randomised, placebo, controlled clinical trial of Co-careldopa in addition to routine
NHS occupational therapy and physical therapy as part of early stroke rehabilitation.
Participants will be randomised on a 1:1 basis to either Co-careldopa or placebo.
The primary objective of the trial is to determine whether the addition of six weeks
of Co-careldopa treatment to rehabilitation therapy can improve the proportion of
patients who can walk independently eight weeks post-randomisation.
Discussion
The DARS trial will provide evidence as to whether Co-careldopa, in addition to routine
NHS occupational and physical therapy, leads to a greater recovery of motor function,
a reduction in carer dependency and advance rehabilitation treatments for people with
stroke.
Trial registration: ISRCTN99643613 assigned on 4 December 2009.
No comments:
Post a Comment